Financial Performance - In 2023, Asymchem Laboratories achieved a total revenue growth of 23.67% year-on-year, excluding the impact of large orders[7]. - The company's revenue for the year ended December 31, 2023, was approximately RMB 7,781,436 thousand, a decrease of 23.94% compared to RMB 10,230,186 thousand for the year ended December 31, 2022[18]. - Gross profit for the reporting period was approximately RMB 3,959,636 thousand, down 18.06% from RMB 4,832,588 thousand in the previous year[18]. - Net profit attributable to shareholders for the reporting period was approximately RMB 2,268,811 thousand, a decline of 31.28% from RMB 3,301,635 thousand in the prior year[18]. - The gross margin for the reporting period improved to 50.89%, compared to 47.24% in the previous year[19]. - Adjusted net profit attributable to shareholders was RMB 2,302.09 million, a decrease of 23.23% compared to 2022[80]. - The company reported a significant increase in revenue, achieving a total of $1.2 billion for the fiscal year, representing a 15% year-over-year growth[165]. - The company reported a 5% increase in gross margin, reaching 45% for the fiscal year[165]. Business Growth and Development - Revenue from small molecule CDMO business grew by 75.56% year-on-year, indicating strong collaboration with multinational pharmaceutical companies[7]. - The company celebrated its 25th anniversary in 2023, marking significant commercial breakthroughs and major orders in the small molecule CDMO sector[7]. - The company has increased its production capacity in China, including commercial production capabilities for peptides and ADCs, to meet the demands of emerging businesses[13]. - The company reported a significant increase in employee count from 3,840 at the end of 2019 to 9,788 currently, reflecting its growth trajectory[16]. - The company aims to expand its global presence and is optimistic about the recovery of domestic markets and the growth of emerging businesses[13]. - The company aims to enhance operational efficiency and reduce costs while expanding its market presence in Europe and Japan[24]. - The company aims to diversify its multinational pharmaceutical client base and has made significant breakthroughs in the Japanese market after years of penetration[36]. - The company has established long-term partnerships with 16 out of the top 20 global pharmaceutical companies, demonstrating strong customer loyalty[132]. Research and Development - Continuous production technology and synthetic biology technology have been developed into comprehensive platforms for external technology output, enhancing efficiency and reducing costs[9]. - The company is prioritizing the advancement of its R&D platform to maintain its leading technological position in the industry[9]. - R&D expenditure exceeded RMB 707.86 million, accounting for 9.10% of total revenue, with plans for continued investment in R&D[61]. - The establishment of the biopharmaceutical technology center (CBTI) in Shanghai aims to enhance R&D capabilities and improve process development[56]. - The company has published 41 research papers in leading international journals, with 14 papers having an impact factor exceeding 10[60]. - The company is committed to continuous R&D investment to strengthen its technology-driven approach and maintain its competitive edge in the CDMO sector[137]. Market Trends and Challenges - The global innovation drug development landscape faced challenges in 2023, impacting the entire CXO industry[6]. - Asymchem's strategic deployment has strengthened its capabilities despite the pressures from market uncertainties[6]. - The company is currently conducting 356 clinical research projects, with 123 in Phase II or later[53]. - The company faces potential risks including major innovative drug recalls, operational challenges in clinical projects, and core technical personnel turnover[149]. Operational Efficiency and Cost Management - The company aims to maximize the utilization of newly added production capacity while minimizing raw material waste and reducing operating costs[72]. - Sales costs for 2023 were RMB 3,821.80 million, a decrease of 29.19% compared to RMB 5,397.60 million in 2022, attributed to improved gross margins and strict cost control measures[84]. - The overall gross margin increased by 3.65% to 50.92% in 2023, driven by a higher gross margin from commercial projects and effective cost management[86]. - The company emphasizes optimizing profitability by improving the gross margin of its small molecule CDMO business and controlling production costs through efficiency and management[145]. Strategic Initiatives - The company is actively seeking investments to enrich its service offerings and expand its overseas presence, focusing on commercial production for multinational companies[141]. - The company plans to enhance its delivery capabilities and expand overseas markets by strengthening management and operational systems[146]. - The company aims to deepen relationships with existing clients while expanding its global customer base, particularly targeting small and medium-sized innovative pharmaceutical companies[139]. - The company is focused on diversifying into new drug categories and service types, including biopharmaceutical CDMO services and clinical research[140]. Corporate Governance and Management - The management team has an average of over 20 years of experience in their respective fields, contributing to stable governance and strategic direction[136]. - Zhang Da serves as the Chief Financial Officer and Chief Operating Officer, responsible for financial operations and investment activities[153]. - The supervisory board consists of three members, including two shareholder representatives and one employee representative[162]. Dividend and Shareholder Information - The company plans to distribute a final dividend of RMB 1.80 per share, totaling approximately RMB 664,080,355.80, subject to shareholder approval[18]. - The board proposed a profit distribution plan for 2023, recommending a dividend of RMB 18.00 per 10 shares of common stock, totaling approximately RMB 664,080,355.80 (including tax) based on 369,471,533 shares issued[186]. - The proposed profit distribution plan for 2023 is subject to approval at the annual general meeting of shareholders and is expected to be paid within two months after the meeting[186].

公 司 研 证券研究报告 究 ＃industryId＃ 医药生物 ＃investSuggestion＃ ＃ ＃dyC凯om莱pan英y＃ （002821.SZ ） investSug 增持 ( 维ges持tionC）h 000009 ＃title＃ 大订单交付顺利，各项业务保持向好趋势 ange＃ ＃createTime1＃ 2024年4 月 8日 投资要点 公 ＃市场ma数rk据etData＃ ＃summary＃  近日，凯莱英发布了2023年年报。2023年公司实现营业收入78.25亿元， 司 日期 2024-04-03 同比下降23.70%；实现归母净利润22.69亿元，同比下降31.28%；实现 点 收盘价（元） 85.09 扣非归母净利润21.04亿元，同比下降34.87%；实现经营现金流净额35.5 评 总股本（百万股） 369.47 亿元，同比增长8.00%。 报 流通股本（百万股） 328.24 告 净资产（百万元） 17479.72  点评：2023年，境内外生物医药融资环境持续低迷，公司顺利实现大订 总资产（百万元） 单交付后，剔除大订单业务实现稳健增长。其中，小分子商业化项目收 19 ...

Dividend and Profit Distribution - The company plans to distribute a cash dividend of 18 RMB per 10 shares (including tax) to all shareholders, with no bonus shares issued[2]. - The company has a comprehensive profit distribution plan approved by the board, ensuring shareholder returns[2]. - The total cash dividend amount for the reporting period was approximately ¥664,080,355.80, which accounted for 100% of the total profit distribution[157]. - The distributable profit for the year was reported at approximately ¥1,142,924,652.86[157]. - The company did not issue any bonus shares or increase capital through reserves during the reporting period[157]. - The company implemented a cash dividend policy for 2023, distributing no less than 10% of the distributable profit achieved during the year[155]. - The company has a clear and transparent decision-making process regarding profit distribution, in compliance with its articles of association and shareholder resolutions[156]. Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB in 2023, representing a year-over-year growth of 25%[8]. - The company's operating revenue for 2023 was ¥7,825,190,298.27, a decrease of 23.70% compared to ¥10,255,325,392.82 in 2022[14]. - The net profit attributable to shareholders for 2023 was ¥2,268,810,444.07, down 31.28% from ¥3,301,635,019.64 in 2022[14]. - The gross margin improved to 45%, up from 40% in the previous year, reflecting enhanced operational efficiency[8]. - The company reported a basic earnings per share of ¥6.26, down 30.60% from ¥9.02 in 2022[14]. - The total revenue for the reporting period reached 7.825 billion CNY, with a year-on-year growth of 24.37% after excluding large orders[36]. - The gross profit margin for 2023 was 51.16%, an increase of 3.79 percentage points year-on-year[36]. - The company reported a significant net profit of ¥1,787,260,413.25 from its subsidiary Jilin Kailai Ying Pharmaceutical Chemical Co., Ltd., contributing over 10% to the overall net profit[99]. Market Expansion and Strategic Initiatives - The company plans to expand its market presence in Europe and North America, targeting a 15% increase in market share by 2025[8]. - The company provided guidance for 2024, projecting a revenue growth of 20% to 1.8 billion RMB, driven by new product launches and market expansion[8]. - The company is actively exploring and laying out new business areas while maintaining its leadership in the pharmaceutical outsourcing industry[25]. - The company is focusing on expanding its overseas market and enhancing the design and manufacturing of continuous reaction equipment, promoting its application across multiple fields[107]. - The company completed a strategic acquisition valued at $300 million, enhancing its product portfolio[129]. - The company is investing $50 million in R&D for new technologies and product development[133]. Research and Development - The company is committed to technological innovation and commercialization in pharmaceutical processes[2]. - Research and development efforts focused on innovative drug formulations, with an investment of 200 million RMB in 2023, aimed at enhancing product efficacy[8]. - The company invested 708 million yuan in R&D in 2023, accounting for 9.05% of its revenue, with a total of 383 authorized patents, including 319 domestic and 64 international patents[55]. - The company is focusing on developing ADC drug technologies, with significant investments in payload and linker research to enhance drug efficacy[75]. - The company has established a robust operational and quality management system that meets the highest global industry standards, ensuring efficient project management and quality control[32]. Risk Management and Compliance - The company faces various risks, including the potential withdrawal or recall of major innovative drugs, operational risks in clinical projects, and regulatory scrutiny from international drug authorities[2]. - The report emphasizes the importance of maintaining core technical personnel to mitigate operational risks[2]. - The company emphasizes compliance with corporate governance standards and continuously improves its internal control systems[112]. - The company has implemented a comprehensive risk management and compliance management system to enhance the effectiveness of its internal control system[167]. - The company has not provided any guarantees or financial assistance to the controlling shareholder, ensuring operational independence[117]. Environmental Responsibility - The report highlights the importance of environmental and safety responsibilities in the company's operations[5]. - The company has established comprehensive waste treatment facilities in accordance with national and local standards, ensuring stable operation[174]. - The company has been recognized as a national-level "green factory" by the Ministry of Industry and Information Technology, being the only one in the Tianjin region to receive this designation[186]. - The company has implemented air pollution control measures, including activated carbon adsorption and RTO systems, to treat emissions from research and production processes[190]. - The company has committed to maintaining compliance with national and local environmental protection laws and regulations[186]. Corporate Governance - The report outlines the company's governance structure, including the roles of the board of directors and supervisory board[3]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with regulatory requirements and maintaining the rights of all shareholders[114]. - The company has established a complete and independent financial accounting system, with no shared bank accounts with the controlling shareholder, ensuring financial independence[118]. - The company has a dedicated internal audit department that supervises the execution of internal control systems and major expenditures, enhancing operational compliance[116]. - The company has established a robust investor relations management system, ensuring timely and accurate information disclosure to investors[115]. Employee and Talent Management - The company introduced 205 senior talents during the reporting period, including 83 PhDs and 93 individuals with overseas pharmaceutical experience, increasing the proportion of employees with a bachelor's degree or above to approximately 78%[62]. - The number of R&D personnel increased by 2.06% to 4,752, with the proportion of R&D personnel in the total workforce rising to 48.55%[76]. - The company has established a competitive compensation system aligned with its strategic goals, incorporating basic salary, performance bonuses, and other incentives[153]. - The training program is designed to enhance employee capabilities and efficiency, focusing on leadership, execution, and competency development through diverse training projects[154]. Communication and Investor Engagement - The company engaged with over 300 institutional investors during a communication event on March 31, 2023, discussing its overall business performance for 2022[110]. - The company held a communication event on April 21, 2023, where it addressed investor inquiries regarding its overall business performance for 2022[110]. - The company communicated its overall business performance for the first half of 2023 to institutional investors on August 30, 2023[111]. - The company reported engaging with over 400 institutional investors on October 31, 2023, to discuss its performance for the first three quarters of 2023[111]. Production Capacity and Infrastructure - A new manufacturing facility is under construction, expected to increase production capacity by 50% by the end of 2024[8]. - The company is expanding its production capacity, with a new dedicated production workshop for chemical macromolecules successfully launched, and plans to increase solid-phase synthesis capacity to 14,250L by June 2024[46]. - The company has established a commercial production center for ADC and mAb in Shanghai and a plasmid and mRNA R&D base in Suzhou to meet growing domestic and international demand[27]. Industry Trends and Market Insights - The global pharmaceutical market is projected to reach $1,718.8 billion by 2025, with a compound annual growth rate of 4.2%[21]. - The global CDMO market size is forecasted to reach $124.3 billion by 2025 and $231.0 billion by 2030, with a CAGR of 13.2%[22]. - The CDMO industry is expected to maintain high growth rates, driven by increasing global R&D investments and the rising demand for innovative drugs[102].

Financial Performance - Total revenue for 2023 was RMB 7,781.44 million, a decrease of 23.94% compared to RMB 10,230.19 million in 2022[6] - Gross profit for 2023 was RMB 3,959.64 million, down 18.06% from RMB 4,832.59 million in 2022, with a gross margin of 50.89%, an increase of 3.65% year-on-year[6] - Net profit attributable to shareholders for 2023 was RMB 2,268.81 million, a decline of 31.28% from RMB 3,301.64 million in 2022, resulting in a net profit margin of 29.16%[6] - Adjusted net profit attributable to shareholders was RMB 2,302.09 million, down 23.23% from RMB 2,998.81 million in 2022, with an adjusted net profit margin of 29.58%[6] - The company confirmed 40 commercial projects generating revenue of RMB 5,107.49 million, a decline of 32.51% year-on-year[78] - Net profit decreased by 31.68% from RMB 3,294.63 million in 2022 to RMB 2,250.82 million in 2023, with a net profit margin of 29.16% compared to 32.27% in 2022[94] - Basic and diluted earnings per share fell from RMB 9.00 in 2022 to RMB 6.26 in 2023, reflecting the decline in net profit[95] Revenue Breakdown - Revenue from small molecule CDMO services was RMB 6,605.14 million, with remaining revenue (excluding large orders) of RMB 4,184.62 million, reflecting a year-on-year growth of 25.47%[11] - Revenue from multinational pharmaceutical companies was RMB 4,988.48 million, a decrease of 32.20%, but excluding large orders, revenue increased by 75.56% to RMB 2,567.96 million[12] - Revenue from U.S. customers was RMB 2,846.75 million, showing a significant year-on-year increase of 47.84%[15] - Emerging business segment revenue reached RMB 1,170.20 million, representing a year-on-year growth of 17.79%[11] - Revenue from overseas markets was RMB 6,344.16 million, a decrease of 26.83% year-on-year, but grew by 41.41% after excluding large orders[81] R&D and Innovation - Research and development expenditure exceeded RMB 707.86 million, accounting for 9.10% of total revenue[53] - The company has developed over 2,700 existing engineered enzymes, with more than 1,100 proprietary enzymes, and successfully developed 17 types of enzyme reagent kits for rapid screening[41] - The company has published 41 research papers in leading international journals, with 14 papers having an impact factor exceeding 10[52] - The launch of the Biological Science Technology Center (CBTI) in May 2023 aims to enhance internal R&D capabilities and streamline process development[140] - The company plans to increase R&D investment and establish an iterative development platform to enhance process synthesis design and optimization[153] Market Position and Strategy - The company has established partnerships with 16 of the top 20 multinational pharmaceutical companies, with 8 of these relationships exceeding 10 years[25] - The company aims to deepen service offerings and expand its client base, particularly in the Japanese market, which has shown significant growth in 2023[27] - The company is focusing on enhancing clinical project reserves to ensure long-term growth, with a strategic emphasis on potential blockbuster projects in the clinical III phase[24] - The company aims to leverage its advanced R&D platforms and strong production capabilities to further enhance its market leadership in the small molecule CDMO sector[137] - The company is actively diversifying into areas such as macromolecular drugs, drug formulation services, and clinical research services, which are expected to open new growth avenues[145] Operational Efficiency - The company is actively optimizing the process development cycle to enhance delivery quality and efficiency, with multiple patents currently under application[49] - The company aims to enhance delivery capabilities and expand overseas markets by accelerating the development of emerging services, focusing on small nucleic acids, peptides, and ADC commercialization production capacity[152] - The company is focusing on creating potential technological advantages through the development of an AI protein design platform[43] - The company has expanded its lipid nanoparticle technology platform and is continuously developing various complex formulation technology platforms, including nasal sprays and aerosol inhalation solutions[36] - The company is committed to balancing economic benefits with social and environmental responsibilities, ensuring a transparent governance structure[72] Corporate Governance - The company has adopted corporate governance principles and believes it has complied with all except one guideline during the reporting period[162] - The roles of the chairman and CEO are held by the same individual, which the board believes does not compromise the balance of power within the company[163] - The board emphasizes high standards of corporate governance to protect shareholder interests and enhance corporate value[164] - The company has confirmed compliance with the standard code for securities trading throughout the fiscal year ending December 31, 2023[166] - The board proposed a final dividend of RMB 18.00 per 10 shares for the year ending December 31, 2023, totaling approximately RMB 664,080,355.80 (including tax), compared to RMB 656,437,642.20 in 2022[176]

Financial Performance - The company's revenue for Q3 2023 was ¥1,761,546,766.74, a decrease of 36.41% compared to the same period last year[6]. - Net profit attributable to shareholders was ¥523,736,701.20, down 46.60% year-on-year[6]. - The total revenue for the first nine months of 2023 reached ¥6,383,057,146.18, reflecting an 18.29% decline year-on-year, but a 24.51% increase when excluding large orders[8]. - The small molecule CDMO business generated revenue of ¥5,565,000,000, a decrease of 22.01% year-on-year, but a 25.45% increase when excluding large orders[8]. - Emerging business revenue was ¥813,000,000, showing a year-on-year growth of 21.05%[8]. - Total operating revenue for Q3 2023 was CNY 6,383,057,146.18, a decrease of 18.3% compared to CNY 7,811,575,256.14 in the same period last year[22]. - Net profit for Q3 2023 was CNY 2,200,808,678.45, a decline of 19.1% compared to CNY 2,720,936,643.42 in Q3 2022[23]. Assets and Liabilities - The company's total assets increased to ¥19,764,226,099.24, an 8.36% rise from the end of the previous year[6]. - The company reported a total asset increase to CNY 19,764,226,099.24 as of September 30, 2023, up from CNY 18,239,273,651.93 at the beginning of the year[21]. - Current assets rose to CNY 13,059,172,427.71, an increase of 10.1% from CNY 11,860,458,372.35[20]. - The total liabilities decreased to CNY 2,292,382,441.40 from CNY 2,544,270,867.15, a reduction of 9.9%[21]. Earnings and Shareholder Information - Basic earnings per share for Q3 2023 were ¥1.45, down 43.84% compared to the same period last year[6]. - Basic and diluted earnings per share were both CNY 6.1, down from CNY 7.46 and CNY 7.43 respectively in the previous period[24]. - The total number of ordinary shareholders at the end of the reporting period was 50,563, with no preferred shareholders[15]. - The largest shareholder, ASYMCHEM LABORATORIES, holds 31.15% of the shares, totaling 115,133,168 shares[16]. Cash Flow and Investments - Cash flow from operating activities for the first nine months was ¥2,864,254,599.72, a slight increase of 0.90%[6]. - Cash received from operating activities rose by 303.43% to ¥172,736,270.48, primarily due to an increase in government subsidies related to capital[13]. - Cash inflow from investment activities totaled approximately CNY 20.10 billion, significantly higher than CNY 2.40 billion in the previous period[27]. - Cash outflow from investment activities was approximately CNY 21.00 billion, compared to CNY 5.08 billion in the previous period, resulting in a net cash flow from investment activities of approximately -CNY 895 million[27]. - The company received CNY 136.30 million in investment income, a recovery from a loss of CNY 4.38 million in the previous period[25]. Expenses and Costs - For the first nine months of 2023, the company's tax and additional charges increased by 59.61% to ¥59,382,485.19 compared to ¥37,204,484.78 in the same period of 2022, primarily due to additional taxes from export tax rebates[13]. - Sales expenses rose by 44.38% to ¥138,989,428.90, driven by continued market expansion and investments in the sales team and marketing activities[13]. - Cash outflow for purchasing goods and services decreased by 56.70% to ¥1,570,814,104.79, reflecting a reduction in large-scale raw material purchases compared to the previous year[13]. - Research and development expenses for Q3 2023 were CNY 513,114,161.26, an increase of 16.1% compared to CNY 442,204,004.98 in Q3 2022[22]. Other Financial Metrics - The weighted average return on equity was 3.18%, a decrease of 3.19% year-on-year[6]. - The total comprehensive income for the period was approximately CNY 2.21 billion, a decrease from CNY 2.75 billion in the previous period[24]. - The company’s capital reserve decreased to CNY 9,634,892,679.05 from CNY 10,143,534,669.29, a decline of 5.0%[21]. - The company’s deferred income tax assets increased to CNY 252,904,157.45 from CNY 177,857,982.20, a growth of 42.1%[20].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依 賴該等內容而引致之任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6821) 二零二三年第三季度報告 本公告乃由凱萊英醫藥集團（天津）股份有限公司（「公司」或「本公司」，連同其 附屬公司「本集團」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第 13.09條及第13.10B條以及證券及期貨條例（香港法例第571章）第XIVA部項下的 內幕消息條文（定義見上市規則）而作出。 茲載列本公司在深圳證券交易所網站刊發的《凱萊英醫藥集團（天津）股份有限公 司二零二三年第三季度報告》，僅供參閱。本公司二零二三年第三季度報告（「二 零二三年第三季度報告」）以中、英文雙語編製。如兩個版本有任何不相符之處， 應以中文版本為準。 本公司董事（「董事」）會（「董事會」）提醒本公司股東及潛在投資者，本公告所載 ...

Financial Performance - Revenue for the six months ended June 30, 2023, was RMB 4,595,708, a decrease of 8.71% compared to RMB 5,034,065 for the same period in 2022[18]. - Net profit attributable to shareholders was RMB 1,686,368, a decrease of 3.09% from RMB 1,740,095 in the prior year, with a net profit margin of 36.7%[18]. - Basic earnings per share for the first half of 2023 were RMB 4.65, down from RMB 4.75 in the previous year[18]. - The total revenue for the reporting period reached RMB 4.596 billion, with a year-on-year growth of 32.71% after excluding large orders[22]. - The company confirmed revenue from 34 commercial projects totaling RMB 3.209 billion, with a year-on-year growth of 60.50% after excluding large orders[28]. - The net profit for the first half of 2023 was RMB 1,686,368 thousand, compared to RMB 1,740,095 thousand in the same period of 2022, indicating a decrease of about 3.09%[179]. - Revenue from a single major customer for the six months ended June 30, 2023, was approximately RMB 2,225,728,303, down from RMB 3,212,304,000 for the same period in 2022, indicating a decrease of about 30.73%[192]. Profitability and Margins - Gross profit increased to RMB 2,426,685, representing a gross margin of 52.8%, up from 46.9% in the previous year[18]. - Adjusted net profit attributable to shareholders rose to RMB 1,636,426, reflecting a 6.44% increase from RMB 1,537,478 in the previous year[18]. - The overall gross margin increased by 6 percentage points to 52.85%, driven by improved margins on commercial projects and effective cost management[64]. - The adjusted net profit attributable to shareholders for the same period was RMB 1,636,426 thousand, compared to RMB 1,537,478 thousand in 2022, resulting in an adjusted net profit margin of 35.61%, up from 30.54%[85]. Revenue Breakdown - Revenue from small molecule CDMO business was RMB 4.064 billion, with a year-on-year growth of 32.41% after excluding large orders[22]. - Emerging business revenue reached RMB 528 million, showing a year-on-year increase of 34.33%[22]. - Revenue from US market customers was RMB 3.329 billion, with a year-on-year growth of 44.17% after excluding large orders[23]. - Revenue from clinical and pre-clinical CDMO solutions was RMB 854,544,000 for the first half of 2023, down from RMB 966,407,000 in 2022, reflecting a decrease of approximately 11.56%[197]. - Revenue from commercial stage CDMO solutions was RMB 3,209,311,000, a decrease of 12.59% from RMB 3,670,602,000 in the previous year[197]. Research and Development - The company invested RMB 323 million in R&D during the first half of 2023, representing a year-on-year increase of 22.84%[42]. - Research and development expenses rose by 23% to RMB 323.5 million, reflecting the company's commitment to technological innovation and core technology development[69]. - The company is committed to strengthening its R&D platform, utilizing iterative computing capabilities to support cross-departmental collaboration in process, engineering, and equipment[104]. Market and Business Strategy - The company is actively exploring new business areas, including chemical macromolecule CDMO and clinical CRO services[21]. - The company aims to expand its market influence by enhancing collaboration with multinational pharmaceutical companies and increasing penetration in the Japanese market[100]. - The business plan for 2023 focuses on deepening relationships with large clients, exploring small and medium-sized clients, and expanding into European and Japanese markets[99]. - The company is committed to a technology-driven strategy, emphasizing the continuous growth of its core small molecule CDMO business while developing strategic emerging industries[99]. Operational Efficiency - The company aims to optimize production processes continuously to reduce costs and improve efficiency, ensuring stable product quality and supply[20]. - The company has developed a modular solution for automated control of temperature, pressure, and pH, significantly improving production efficiency[45]. - The company is focused on integrating digital platforms and predictive capabilities to optimize production processes and enhance operational efficiency[43]. Financial Position - Cash and bank balances increased by RMB 1,752 million, a growth of 33%, mainly due to net cash inflow from operating activities of RMB 2,253 million[73]. - The asset-liability ratio decreased from 13.9% at the end of 2022 to 12.5% by June 30, 2023[78]. - Total assets increased by 4% to RMB 5,039,078 thousand, primarily due to the conversion of construction in progress[80]. - The company's total equity reached RMB 16,791,971 thousand, an increase from RMB 15,695,003 thousand as of December 31, 2022, representing a growth of approximately 6.96%[177]. Risks and Challenges - The company acknowledges potential risks related to the market exit or recall of major innovative drugs, emphasizing the need for proactive risk management[108]. - The company is aware of the uncertainties in the commercialization prospects of its clients' drugs, which may lead to lower-than-expected sales[109]. - The company faces risks related to international trade tensions and has planned effective backup measures to mitigate potential adverse effects[113]. Employee and Governance - The company introduced 73 senior talents during the reporting period, including 32 PhDs and 31 individuals with overseas pharmaceutical experience[49]. - The company emphasizes a "people-oriented" approach, focusing on employee rights and welfare, and has implemented stock incentive plans to boost employee motivation[53]. - The group had 9,145 employees as of June 30, 2023, with competitive compensation packages based on performance and market rates[157]. Shareholder Information - The board does not recommend the payment of an interim dividend for the six months ending June 30, 2023[124]. - The company has granted a total of 3,327,450 restricted A shares under the A-share equity incentive plan as of June 30, 2023, representing approximately 0.90% of the total issued shares[143].

Financial Performance - The company reported a significant increase in revenue for the first half of 2023, with a total revenue of RMB 1.5 billion, representing a year-on-year growth of 25%[4]. - The gross profit margin improved to 35%, up from 30% in the same period last year, indicating better cost management and operational efficiency[4]. - Asymchem reported a revenue increase of 25% year-over-year for the first half of 2023, reaching approximately CNY 1.5 billion[18]. - The company reported a net profit of CNY 400 million for the first half of 2023, representing a 30% increase compared to the same period last year[18]. - The company reported a total revenue of 231,057 million, with a year-on-year increase of 23.21%[91]. - The company reported a total revenue of 1.2 billion RMB for the first half of 2023, representing a year-on-year increase of 15%[123]. - The company anticipates a revenue growth forecast of 20% for the full year 2023, driven by increased demand for its services and products[18]. - Future guidance indicates an expected revenue growth of 30% for the second half of 2023, driven by increased demand for contract manufacturing services[4]. Market Expansion and Client Growth - User data showed an increase in active clients, reaching 200, with a 15% increase compared to the previous half-year[4]. - The company plans to expand its market presence in Europe and North America, targeting a 20% increase in market share by the end of 2024[4]. - The company expanded its client base by 15%, now serving over 300 pharmaceutical and biotech companies globally[18]. - The company has established partnerships with 15 of the top 20 global pharmaceutical companies, with 8 of them being served for over 10 years[42]. - The company has a total of over 1,100 active clients, with a 21.21% increase in order clients[49]. Research and Development - The company has allocated RMB 200 million for R&D in new technologies, focusing on enhancing drug delivery systems and improving production processes[4]. - Asymchem's R&D investment for the first half of 2023 was CNY 200 million, accounting for 13% of total revenue, aimed at enhancing its innovative drug development capabilities[18]. - The company plans to launch three new products in the next quarter, focusing on antibody-drug conjugates (ADCs) and mRNA-based therapies[18]. - The company is investing 200 million RMB in R&D for new technologies aimed at enhancing product efficiency and sustainability[123]. - R&D investment reached 323 million yuan, a year-on-year increase of 22.84%[66]. Strategic Acquisitions and Partnerships - The company is actively pursuing strategic acquisitions to enhance its service offerings, with a target of completing at least two acquisitions by the end of 2023[4]. - The company is actively pursuing strategic partnerships and collaborations to enhance its market presence and technological capabilities[18]. - The company has completed two strategic acquisitions in the last quarter, which are expected to enhance its market position and product offerings[123]. Environmental Compliance and Sustainability - The company emphasizes the importance of safety and environmental management, implementing a comprehensive safety responsibility system to reduce risks[99]. - The company is committed to sustainable development through the adoption of green chemistry technologies, aiming to reduce waste emissions and enhance production safety[103]. - The company has established a comprehensive cGMP standard quality system to ensure consistent product quality and compliance with international pharmaceutical standards[102]. - The company has implemented various energy-saving and emission-reduction measures, including technological innovation and equipment upgrades[148]. - The company has adopted a strategy of "international standards, Chinese advantages, technology-driven, and green-based" for its development[129]. Financial Strategy and Shareholder Returns - The company has no plans to distribute cash dividends or issue bonus shares for this fiscal year, focusing instead on reinvestment for growth[6]. - The company has approved the repurchase and cancellation of 67,620 restricted A-shares as part of its stock incentive plan[109]. - The company is committed to continuous cash distribution plans to ensure reasonable returns for investors while maintaining normal operations[150]. - The company has committed to reducing registered capital through share cancellations as part of its financial strategy[187]. Risk Management - The management highlighted potential risks, including regulatory challenges and market competition, which could impact future performance[4]. - The company faces risks related to the potential withdrawal or recall of major innovative drugs, which could reduce demand for its pharmaceutical intermediates[97]. - The company acknowledges the high failure risk associated with the R&D of innovative drugs and biosimilars, which requires enhanced business expansion and risk identification capabilities[98]. Employee and Talent Development - The company recruited 73 senior talents during the reporting period, including 32 PhDs and 31 individuals with overseas pharmaceutical experience[74]. - As of the end of the reporting period, the company employed 9,145 people, with approximately 75% holding a bachelor's degree or higher[74]. - The company has established a diversified and transparent talent development platform, focusing on employee rights and welfare[150]. Operational Efficiency - The company achieved a gross profit margin of 35%, reflecting a stable performance in its core business segments[18]. - Operating costs decreased by 18.79% to ¥2,169,022,833.17 from ¥2,670,840,289.22, contributing to improved profitability[77]. - The company reported a net increase in cash and cash equivalents of ¥1,133,950,181.26, a 152.19% improvement from a decrease of ¥2,172,920,218.69 in the prior year[78]. Corporate Social Responsibility - The company actively participates in social welfare activities, including medical rescue and rural revitalization efforts, reflecting its commitment to corporate social responsibility[152]. - The company has implemented annual environmental monitoring plans, with third-party qualified units conducting regular monitoring of waste emissions and environmental impact[144][145][146].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Asymchem Laboratories (Tianjin) Co., Ltd. 凱萊英醫藥集團（天津）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6821） 截至二零二三年六月三十日止六個月 中期業績公告 凱萊英醫藥集團（天津）股份有限公司（「本公司」、「公司」、「凱萊英」）董事（「董 事」）會（「董事會」）欣然公佈本公司及其附屬公司（統稱「本集團」、「我們」）截至 二零二三年六月三十日止六個月（「報告期」）的未經審計綜合中期業績，連同截至 二零二二年六月三十日止六個月（「同期」）之比較數字。除非在本公告內另有界 定，否則本公告內詞彙具有招股章程所界定的相同涵義。 本公告所載若干金額及百分比數字已作四捨五入調整，或約整至小數點後一位或 兩位。任何表格、圖表或其他地方所列總數與數額總和之間如有任何差異，皆因 約整所致。 ...

Financial Performance - The company achieved total revenue of CNY 2.25 billion in Q1 2023, representing a year-on-year increase of 9.09%[6] - Net profit attributable to shareholders reached CNY 630.35 million, up 26.22% compared to the same period last year[6] - The net profit excluding non-recurring items was CNY 617.64 million, reflecting a growth of 26.98% year-on-year[6] - Cash flow from operating activities surged to CNY 1.30 billion, a significant increase of 537.09% compared to the previous year[6] - The gross profit margin improved to 48.40%, an increase of 3.16 percentage points from the previous year, with gross profit amounting to CNY 1.09 billion[12] - Revenue from the small molecule CDMO business was CNY 2.00 billion, a year-on-year increase of 4.31%, with a 45.37% growth when excluding large orders[13] - Emerging business revenue reached CNY 249 million, marking a substantial growth of 72.54% year-on-year[14] - Total operating revenue for Q1 2023 reached ¥2,249,034,497.62, an increase of 9.1% compared to ¥2,061,708,856.14 in Q1 2022[24] - Operating profit for Q1 2023 was ¥709,948,636.92, up 24.5% from ¥570,097,662.75 in the same period last year[24] - Net profit attributable to shareholders for Q1 2023 was ¥630,346,004.43, compared to ¥499,398,084.81 in Q1 2022, reflecting a growth of 26.2%[25] - Basic and diluted earnings per share for Q1 2023 were both ¥1.72, an increase from ¥1.36 in Q1 2022[25] Assets and Liabilities - The total assets at the end of the reporting period were CNY 18.55 billion, a 1.69% increase from the end of the previous year[6] - Total current assets amount to ¥11,977,491,343.33, an increase from ¥11,860,458,372.35 at the beginning of the year[21] - Total liabilities decreased to ¥2,176,785,958.74 in Q1 2023 from ¥2,544,270,867.15 in Q1 2022, a reduction of approximately 14.5%[24] - Total equity attributable to shareholders increased to ¥16,324,854,569.41 in Q1 2023, up from ¥15,647,427,643.90 in Q1 2022, representing an increase of 4.3%[24] - The total liabilities and equity combined amounted to ¥18,546,760,048.14 in Q1 2023, compared to ¥18,239,273,651.93 in Q1 2022[24] Cash Flow - The cash inflow from operating activities for Q1 2023 was CNY 2,861,189,791.85, an increase of 48.8% compared to CNY 1,925,864,058.95 in Q1 2022[28] - The net cash flow from operating activities reached CNY 1,303,525,263.66, significantly up from CNY 204,607,061.83 in the same period last year[28] - Cash inflow from investment activities totaled CNY 8,399,828,818.08, compared to CNY 611,137,118.87 in Q1 2022, marking a substantial increase[28] - The net cash outflow from investment activities was CNY 327,218,213.85, an improvement from a net outflow of CNY 1,131,790,662.67 in Q1 2022[28] - The cash flow from financing activities showed a net inflow of CNY 383,841,586.32, with cash outflow for dividend payments recorded at CNY 3,889,772.50[29] - The total cash and cash equivalents at the end of Q1 2023 amounted to CNY 5,379,198,112.41, down from CNY 5,642,739,406.29 at the end of Q1 2022[29] - The company reported a cash inflow from the recovery of investments of CNY 8,368,856,153.32, a significant increase from CNY 607,807,000.00 in the previous year[28] - The cash outflow for purchasing goods and services was CNY 638,798,212.57, a decrease from CNY 1,003,677,026.11 in Q1 2022[28] - The total cash inflow from operating activities was CNY 2,861,189,791.85, while total cash outflow was CNY 1,557,664,528.19, resulting in a net cash flow of CNY 1,303,525,263.66[28] Shareholder Information - Total number of common shareholders at the end of the reporting period is 73,675[16] - ASYMCHEM LABORATORIES, INCORPORATED holds 31.12% of shares, totaling 115,133,168 shares[16] - HAO HONG holds 3.86% of shares, totaling 14,268,699 shares[16] - The company repurchased a total of 5,229,266 shares, accounting for 1.4134% of the total A+H share capital[18] - The company has not completed the transfer procedures for the employee stock ownership plan as of the end of the reporting period[19] Research and Development - Research and development expenses for Q1 2023 were ¥162,096,744.48, compared to ¥130,883,695.56 in Q1 2022, indicating a rise of 23.8%[24] - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[23] Market Expansion - The company plans to expand its market presence in Europe and Japan while focusing on cost control and efficiency improvements[12]